A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Hepatocholangiocarcinoma, Fibrolamellar Carcinoma, Hepatic Epithelioid Hemangioendothelioma, Hepatoblastoma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences. This retrospective cohort will be the backbone of future translational studies aimed at identifying new molecular, histological, circulating and radiological tumor biomarkers, potentially useful at every stage of diagnosis and prognostic or theranostic evaluation.
Detailed description
The aim is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences.
Primary outcome measures
- Description of the clinical, histological and radiological characteristics of various rare primary liver cancers [Time frame: up to 5 years from the date of diagnosis]
Secondary outcome measures (3)
- Recurrence-free survival (for non-metastatic patients) [Time frame: up to 5 years from diagnosis]
- Progression-free survival (for metastatic patients) [Time frame: up to 5 years from diagnosis]
- Overall survival [Time frame: up to 5 years from diagnosis]
Eligibility criteria
Inclusion criteria
- 18 years of age or older,
- with histologically proven hepato-cholangiocarcinoma, fibrolamellar hepatocellular carcinoma, epithelioid hemangioendothelioma or hepatic angiosarcoma
- diagnosed after January 01, 2018 living or deceased at the time of registration in the cohort
- for living patients who have not objected to the research: (note of non-objection to be attached° agreeing to participate in ancillary studies must sign the biological consent form for participation in biological studies.
Exclusion criteria
- without social security
- No access to tumor block
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
France · 40 centers
- CHU Amiens picardie — Amiens
- Chu Angers — Angers
- Ch - Centresimone Veil de Beauvais — Beauvais
- Chu Jean Minjoz — Besançon
- Ch Bethune Beuvry — Béthune
- Avicenne — Bobigny
- Cote de Nacre — Caen
- Centre Hospitalier — Calais
- … and 32 more centers
Identifiers
NCT: NCT06541652 · CAPRIH COHORT · 2023-A01517-38